Azevan Pharmaceuticals is a clinical stage company developing novel therapeutics for disorders of stress, mood, and behavior. The Company's compounds are first-in-class, highly selective, CNS penetrating vasopressin 1a (V1a) receptor antagonists that represent a new mechanism of action for treating disorders such as PTSD, major depression, and impulse control/anger disorders. Two compounds have completed successful Phase I SAD & MAD clinical trials and an experimental medicine fMRI study recently established engagement with target CNS V1a receptors and significant effects in brain circuits implicated in stress-related affective disorders. Progress has been achieved in the face of growing challenges for small companies developing new drugs, including a wider and deeper �valley of death� for partnering and an increasingly risk-averse financing climate, even with major market opportunities. This presentation will cover the staged resource-leveraging business strategy that Azevan utilized to advance its drug development programs in this increasingly difficult climate.

Azevan Pharmaceuticals: CNS drug development in the new normal

244th National Meeting (2012)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.